LUPUS NEPHRITIS

This early-stage study tests a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't responded to standard therapies. The treatment uses specially engineered immune cells to target and destroy fa…

This study tests whether adding obinutuzumab to standard treatment helps people with lupus-related kidney disease (lupus nephritis) achieve better kidney function. About 271 adults with active kidney inflammation took part. The goal was to see if the drug could improve kidney res…

This study planned to test a single infusion of CB-010, a CRISPR-edited immune cell therapy, in people with severe lupus that did not respond to standard treatments. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before any partici…

This study tests a new drug, felzartamab, in 14 people with active lupus nephritis (kidney inflammation caused by lupus). The drug targets immune cells that make harmful antibodies, which build up in the kidneys and cause damage. Participants continue their usual treatments while…

This study tests a new treatment called YTB323 for people with severe lupus that hasn't responded to other therapies. About 21 adults will receive the therapy to see if it is safe and helps control the disease. The goal is to reduce lupus activity, but ongoing management may stil…

This study tests a new drug called povetacicept in people with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if it is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 months, …

This early-phase study tests a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathy that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, modified to target and attack faul…

This early-phase study tests a new treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing severe lupus or scleroderma. About 48 adults with these hard-to-treat autoimmune diseases will receive the therapy to see if it is…

This study aimed to test whether nipocalimab, an experimental drug, could help people with active lupus nephritis (kidney inflammation caused by lupus). The trial was planned for adults with confirmed kidney disease and high protein in their urine. However, the study was withdraw…

This early-phase study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't responded to standard therapies. KYV-101 uses a patient's own immune cells, modified to target and destroy harmful B cells that drive kidney inflammation. The study aims to che…

This early-phase study tests a new treatment called Prula-cel for people with certain autoimmune diseases like lupus and scleroderma. Prula-cel uses specially engineered immune cells from a healthy donor to target and attack faulty immune cells that cause disease. The main goals …

This study tests whether anifrolumab can help adults with active lupus nephritis, a serious kidney condition caused by lupus. About 359 participants will receive either the drug or a placebo to see if it improves kidney function and reduces the need for steroids. The goal is to c…

This early-phase study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells that drive the disease. The main goals are to c…